CN119735682A - 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 - Google Patents

用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 Download PDF

Info

Publication number
CN119735682A
CN119735682A CN202411950244.6A CN202411950244A CN119735682A CN 119735682 A CN119735682 A CN 119735682A CN 202411950244 A CN202411950244 A CN 202411950244A CN 119735682 A CN119735682 A CN 119735682A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
btla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411950244.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·A·扎贝尔
J·A·利平科特
Y·郑
M·V·饶
M·谭
D·P·迈宁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuria Intellectual Property Holdings LLC
Trianni Inc
Original Assignee
Kuria Intellectual Property Holdings LLC
Trianni Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuria Intellectual Property Holdings LLC, Trianni Inc filed Critical Kuria Intellectual Property Holdings LLC
Publication of CN119735682A publication Critical patent/CN119735682A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411950244.6A 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 Pending CN119735682A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962827744P 2019-04-01 2019-04-01
US62/827,744 2019-04-01
CN202080040939.4A CN114585416B (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
PCT/US2020/025936 WO2020205849A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080040939.4A Division CN114585416B (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Publications (1)

Publication Number Publication Date
CN119735682A true CN119735682A (zh) 2025-04-01

Family

ID=70296156

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411950244.6A Pending CN119735682A (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
CN202080040939.4A Active CN114585416B (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080040939.4A Active CN114585416B (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Country Status (8)

Country Link
US (2) US11384146B2 (enExample)
EP (1) EP3946622A1 (enExample)
JP (2) JP7596298B2 (enExample)
KR (1) KR20220047536A (enExample)
CN (2) CN119735682A (enExample)
CA (1) CA3135836A1 (enExample)
IL (1) IL286838A (enExample)
WO (1) WO2020205849A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232480A2 (en) * 2020-10-23 2023-08-30 AnaptysBio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
JP2025501452A (ja) * 2021-12-10 2025-01-22 メルク・シャープ・アンド・ドーム・エルエルシー ヒトメソテリン結合物質
JP2025504012A (ja) * 2022-01-29 2025-02-06 ハイファイバイオ， インク． 抗ｂｔｌａ抗体および癌治療におけるその使用
KR20240139083A (ko) * 2022-01-29 2024-09-20 하이파이바이오 인코퍼레이티드 Btla에 대한 항체 및 이의 용도
US20230322929A1 (en) * 2022-04-12 2023-10-12 Shanghai Junshi Biosciences Co., Ltd. Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
US20260035464A1 (en) * 2022-07-19 2026-02-05 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025250861A1 (en) * 2024-05-31 2025-12-04 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-hcmv antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7153950B2 (en) 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
US7973138B2 (en) * 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
IN2012DN00863A (enExample) * 2009-07-31 2015-07-10 Medarex Inc
CN107108740B (zh) 2014-11-05 2021-09-17 豪夫迈·罗氏有限公司 抗fgfr2/3抗体及其使用方法
JP2018521959A (ja) * 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
EP3383908A1 (en) * 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
JP7184751B2 (ja) * 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用

Also Published As

Publication number Publication date
WO2020205849A1 (en) 2020-10-08
US11384146B2 (en) 2022-07-12
US20230340123A1 (en) 2023-10-26
JP2025041629A (ja) 2025-03-26
CN114585416A (zh) 2022-06-03
JP2022528005A (ja) 2022-06-07
CN114585416B (zh) 2025-01-17
EP3946622A1 (en) 2022-02-09
JP7596298B2 (ja) 2024-12-09
CA3135836A1 (en) 2020-10-08
US20200325230A1 (en) 2020-10-15
IL286838A (en) 2021-10-31
KR20220047536A (ko) 2022-04-18

Similar Documents

Publication Publication Date Title
CN114585416B (zh) 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
JP7260586B2 (ja) 抗ｌａｇ３抗体
US12404327B2 (en) LILRB3-binding molecules and uses therefor
US20240150462A1 (en) Lilrb1 and lilrb2-binding molecules and uses therefor
KR20210138674A (ko) Tsg-6 항체 및 그 용도
TWI857009B (zh) Ｆｃｍｒ結合分子及其用途
EA046937B1 (ru) Lilrb3-связывающие молекулы и варианты их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination